Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2022

View Archived Issues

MAO mutant zebrafish exhibit abnormal brain development

ATR kinase blockade useful for treating pancreatic ductal adenocarcinoma

Idorsia Pharmaceuticals discovers Kv7 potassium channel activators

Charite-Universitaetsmedizin Berlin, Sapreme Technologies present new saponin derivatives

New kappa-opioid receptor agonists identified at Humanwell Pharmaceutical US

Ortho-hIL-2/ortho-hIL-2Rbeta pair enhances antitumor efficacy of engineered T cells

Yes targeting useful for treatment of HCC, researchers suggest

Sodium salt of a quinoline derivative shows anticancer efficacy in vivo

Once-daily dermal administration of Epoladerm well tolerated in four preclinical studies

Eisbach Bio and MD Anderson partner to target synthetic lethality in cancer

ProMIS initiates program to develop monoclonal antibodies to treat schizophrenia

BetterLife reports data from in vivo oral bioavailability and food-effect PK study with BETR-001

Evotec and Lilly collaborate on drug discovery for metabolic diseases

Almirall and IRB Barcelona collaborate on molecular glue degraders for skin diseases

NT-I7 promotes longer survival in murine models of glioma through CD8+ T cells

Subcutaneous nanocarrier-mediated delivery of rapamycin

Amyloid aggregates differ in familial and sporadic AD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...